Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
4.740
-0.480 (-9.20%)
Mar 31, 2025, 1:16 PM EDT - Market open

Company Description

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States.

The company’s product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels.

It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.

The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019.

Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts.

Verve Therapeutics, Inc.
Verve Therapeutics logo
Country United States
Founded 2018
IPO Date Jun 17, 2021
Industry Biotechnology
Sector Healthcare
Employees 274
CEO Sekar Kathiresan

Contact Details

Address:
201 Brookline Avenue, Suite 601
Boston, Massachusetts 02215
United States
Phone 617 603 0070
Website vervetx.com

Stock Details

Ticker Symbol VERV
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001840574
CUSIP Number 92539P101
ISIN Number US92539P1012
Employer ID 82-4800132
SIC Code 2834

Key Executives

Name Position
Dr. Sekar Kathiresan M.D. Co-Founder, Chief Executive Officer and Director
Dr. Burt A. Adelman M.D. Co-Founder and Independent Chairman of the Board
Allison Dorval CPA Chief Financial Officer and Principal Accounting Officer
Andrew D. Ashe J.D. President, Chief Operating Officer and General Counsel
Dr. Kiran Musunuru M.D., M.P.H., Ph.D. Co-Founder
Dr. J. Keith Joung M.D., Ph.D. Co-Founder
Dr. Anthony Philippakis M.D., Ph.D. Co-Founder and Scientific Advisory Board Member
Dr. Barry S. Ticho FACC, M.D., Ph.D. Co-Founder
Issi Rozen M.B.A. Co-Founder and Strategic Advisor
Dr. Troy Lister Ph.D. Chief Scientific Officer

Latest SEC Filings

Date Type Title
Feb 27, 2025 POS AM Post-Effective amendments for registration statement
Feb 27, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 POSASR Filing
Feb 27, 2025 8-K Current Report
Feb 5, 2025 SCHEDULE 13G Filing
Jan 31, 2025 SCHEDULE 13G/A Filing
Jan 10, 2025 SCHEDULE 13G/A Filing
Nov 18, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals